Advances in Nanomaterials Used in Co-Delivery of siRNA and Small Molecule Drugs for Cancer Treatment.

Nanomaterials (Basel)

Center for Cancer and Stem Cell Research, Institute for Research, Development and Innovation (IRDI), International Medical University, Kuala Lumpur 57000, Malaysia.

Published: September 2021

AI Article Synopsis

  • * Co-delivery systems that combine small molecule drugs with short-interfering RNA (siRNA) show promise in effectively suppressing tumor growth, demonstrating a synergistic effect compared to single-drug approaches.
  • * The review categorizes these co-delivery systems by drug carrier materials, explores their critical properties, highlights key examples from recent studies, and discusses emerging issues in biomaterials for cancer treatments.

Article Abstract

Recent advancements in nanotechnology have improved our understanding of cancer treatment and allowed the opportunity to develop novel delivery systems for cancer therapy. The biological complexities of cancer and tumour micro-environments have been shown to be highly challenging when treated with a single therapeutic approach. Current co-delivery systems which involve delivering small molecule drugs and short-interfering RNA (siRNA) have demonstrated the potential of effective suppression of tumour growth. It is worth noting that a considerable number of studies have demonstrated the synergistic effect of co-delivery systems combining siRNA and small molecule drugs, with promising results when compared to single-drug approaches. This review focuses on the recent advances in co-delivery of siRNA and small molecule drugs. The co-delivery systems are categorized based on the material classes of drug carriers. We discuss the critical properties of materials that enable co-delivery of two distinct anti-tumour agents with different properties. Key examples of co-delivery of drug/siRNA from the recent literature are highlighted and discussed. We summarize the current and emerging issues in this rapidly changing field of research in biomaterials for cancer treatments.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540385PMC
http://dx.doi.org/10.3390/nano11102467DOI Listing

Publication Analysis

Top Keywords

small molecule
16
molecule drugs
16
sirna small
12
co-delivery systems
12
co-delivery sirna
8
cancer treatment
8
co-delivery
7
cancer
5
advances nanomaterials
4
nanomaterials co-delivery
4

Similar Publications

MAI-TargetFisher: A proteome-wide drug target prediction method synergetically enhanced by artificial intelligence and physical modeling.

Acta Pharmacol Sin

January 2025

Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, China.

Computational target identification plays a pivotal role in the drug development process. With the significant advancements of deep learning methods for protein structure prediction, the structural coverage of human proteome has increased substantially. This progress inspired the development of the first genome-wide small molecule targets scanning method.

View Article and Find Full Text PDF

Targeted protein degradation (TPD) offers a promising approach for chemical probe and drug discovery that uses small molecules or biologics to direct proteins to the cellular machinery for destruction. Among the >600 human E3 ligases, CRBN and VHL have served as workhorses for ubiquitin-proteasome system-dependent TPD. Identification of additional E3 ligases capable of supporting TPD would unlock the full potential of this mechanism for both research and pharmaceutical applications.

View Article and Find Full Text PDF

Flow chemistry-enabled asymmetric synthesis of cyproterone acetate in a chemo-biocatalytic approach.

Nat Commun

January 2025

Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai, 200433, China.

Flow chemistry has many advantages over batch synthesis of organic small-molecules in terms of environmental compatibility, safety and synthetic efficiency when scale-up is considered. Herein, we report the 10-step chemo-biocatalytic continuous flow asymmetric synthesis of cyproterone acetate (4) in which 10 transformations are combined into a telescoped flow linear sequence from commercially available 4-androstene-3, 17-dione (11). This integrated one-flow synthesis features an engineered 3-ketosteroid-Δ-dehydrogenase (ReM2)-catalyzed Δ-dehydrogenation to form the C1, C2-double bond of A ring, a substrate-controlled Co-catalyzed Mukaiyama hydration of 9 to forge the crucial chiral C17α-OH group of D ring with excellent stereoselectivity, and a rapid flow Corey-Chaykovsky cyclopropanation of 7 to build the cyclopropyl core of A ring.

View Article and Find Full Text PDF

Multi-Resonance 1,4-BN-Heteroarene for Filterless Narrowband Photodetector.

Angew Chem Int Ed Engl

January 2025

Nankai University, College of Chemistry, Weijin Road 94, 300071, Tianjin, CHINA.

As an emerging class of optoelectronic materials, multi-resonance (MR) 1,4-BN-heteroarenes have been extensively employed as narrowband electroluminescence materials, whereas their absorption feature has largely been neglected. Here we construct the first MR-molecule-based phototransistor for filterless narrowband photodetectors (NBPDs) by anchoring narrowband absorption MR molecules on the high-mobility semiconductor indium-zinc-oxide (IZO) film. The resulting device exhibits high-performance photodetection with a small full-width at half-maximum (FWHM) of 33 nm, which represents a new record for NBPDs based on intrinsic narrowband absorbing materials.

View Article and Find Full Text PDF

Aptazyme-directed A-to-I RNA editing.

Methods Enzymol

January 2025

Natural Products Research Center, Chengdu Institute of Biology, Chinese Academy of Science, Chengdu, P.R. China. Electronic address:

As a promising therapeutic approach, the RNA editing process can correct pathogenic mutations and is reversible and tunable, without permanently altering the genome. RNA editing mediated by human ADAR proteins offers unique advantages, including high specificity and low immunogenicity. Compared to CRISPR-based gene editing techniques, RNA editing events are temporary, which can reduce the risk of long-term unintended side effects, making off-target edits less concerning than DNA-targeting methods.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!